AnaptysBio Inc (NAS:ANAB)
$ 13.04 -0.7 (-5.09%) Market Cap: 396.79 Mil Enterprise Value: 4.47 Mil PE Ratio: 0 PB Ratio: 4.71 GF Score: 59/100

AnaptysBio Inc to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event Transcript

Oct 25, 2023 / 08:15PM GMT
Release Date Price: $17.62 (-0.17%)
Operator

Good day, and thank you for standing by. Welcome to the Anaptys PD-1 Agonist Rosnilimab R&D Event Webcast. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to Dan Faga, President and Chief Executive Officer of Anaptys.

Daniel R. Faga
AnaptysBio, Inc. - President, CEO & Director

Welcome, everyone. We are excited to host today's event focused on rosnilimab, our internally discovered PD-1 agonist. This presentation will contain statements that are forward looking. We're going to review what are massive opportunities for rosnilimab with a best-in-class profile in rheumatoid arthritis, where there is proof-of-concept for this mechanism and announcing today a first-in-class study in ulcerative colitis.

Joining me from Anaptys are Dr. Paul Lizzul, our Chief Medical Officer; Dr. Martin Dahl, our SVP of Research; and Dr. Cailin Sibley, our VP, Translational Medicine. Also, we've had 2 distinguished physicians prerecord their sessions. Dr. Jonathan Graf, Professor

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot